E-LIB Suche - Ergebnisse für: Horowitz, N.

1

REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐..:

Vassilakopoulos, T. ; Ferhanoglu, B. ; Horowitz, N....
Hematological Oncology. 41 (2023) S2 - p. 410-411 , 2023

Link: https://doi.org/10.1002/..

2

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN ..:

Gurion, R. ; Rozovski, U. ; Itchaki, G....
HemaSphere. 6 (2022) - p. 1465-1466 , 2022

Link: https://doi.org/10.1097/..

3

P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMAR..:

Vassilakopoulos, T. ; Ferhanoglu, B. ; Horowitz, N. A....
HemaSphere. 6 (2022) - p. 1114-1115 , 2022

Link: https://doi.org/10.1097/..

4

P1078: PATIENTS WITH HODGKIN LYMPHOMA DEVELOP ADEQUATE HUMO..:

Dann, E. ; Inbar, T. ; Mashiach, T....
HemaSphere. 6 (2022) - p. 968-969 , 2022

Link: https://doi.org/10.1097/..

5

Continuous monitoring of advanced hemodynamic parameters sh..:

Nachman, D ; Eisenkraft, A ; Maor, Y...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

6

RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIA..:

Vassilakopoulos, T. ; Ferhanoglu, B. ; Horowitz, N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

7

MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐L..:

Olszewski, A. J ; Avigdor, A ; Babu, S...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

Patient, treatment and discharge factors associated with ho..:

Dorney, K.M. ; Growdon, W.B. ; Clemmer, J....
Gynecologic Oncology. 144 (2017) 1 - p. 136-139 , 2017

Link: https://doi.org/10.1016/..

9

Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase ..:

Viswanathan, A.N. ; Winter, K. ; Miller, B.E....
International Journal of Radiation Oncology*Biology*Physics. 96 (2016) 2 - p. S49-S50 , 2016

Link: https://doi.org/10.1016/..

10

Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL): ..:

Rule, S. ; Goy, A. ; Martin, P....
Value in Health. 18 (2015) 3 - p. A300-A301 , 2015

Link: https://doi.org/10.1016/..

11

Patient, Treatment and Discharge Factors associated with Ho..:

Dorney, K.M. ; Growdon, W.B. ; Clemmer, J....
Gynecologic Oncology. 139 (2015) 3 - p. 593-594 , 2015

Link: https://doi.org/10.1016/..

12

Investigating the impact of body mass index on intraperiton..:

Davis, M. ; Rauh-Hain, A. ; Worley, M....
Gynecologic Oncology. 136 (2015) 2 - p. 402-403 , 2015

Link: https://doi.org/10.1016/..

13

Abstract number 6: Multiple lines of chemotherapy in recurr..:

Esselen, K. ; Wright, A. ; Kim, J..
Gynecologic Oncology. 134 (2014) 2 - p. 431-432 , 2014

Link: https://doi.org/10.1016/..

14

The impact of obesity and adjuvant chemotherapy regimens on..:

Suri, A. ; Carter, E. ; Edwards, J....
Gynecologic Oncology. 130 (2013) 1 - p. e150 , 2013

Link: https://doi.org/10.1016/..

15

Impact of preoperative and pretreatment CA125 on survival o..:

Horowitz, N. ; Miller, A. ; Rungruang, B....
Gynecologic Oncology. 130 (2013) 1 - p. e20 , 2013

Link: https://doi.org/10.1016/..